FDA Approved Indications for this Orphan Drug:

Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 4 years of age and older.

FDA Marketing Approval issued as of:
02/21/2008

Orphan Drug exclusivity ends on:
02/21/2015
Company Making and Marketing this drug:
AbbVie Inc.

FDA Designation Date:
3/21/05

FDA Drug Designation:
Treatment of juvenile rheumatoid arthritis